Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

Asthma Clinical Trial

Official title:

The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00178152
• Other study ID #: 11627
• Status: Completed
• Phase: N/A
• First received: September 12, 2005
• Last updated: May 11, 2011
• Start date: May 2005
• Est. completion date: November 2005

Study information

• Verified date: May 2011
• Source: University of Rochester
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Erythema Toxicum Neonatorum (ETN) is a common skin finding that affects healthy full-term babies. Several authors have commented on the possible relationship between ETN and the development of atopic conditions, such as atopic dermatitis or respiratory disease later in life. There is a paucity of research addressing this issue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 334
• Est. completion date: November 2005
• Est. primary completion date: November 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Years to 9 Years

Eligibility

Inclusion Criteria:

• Children between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years.

• Control subjects will be age matched and without an asthma diagnosis.

Exclusion Criteria:

• Children without accessible medical records

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Asthma
• Erythema
• Erythema Toxicum Neonatorum

Locations

Country	Name	City	State
United States	Department of Pediatrics, University of Rochester	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
University of Rochester

Country where clinical trial is conducted

United States,